Pet evaluation of the dopamine system of the human brain

Journal of Nuclear Medicine

Volumn 37, Issue 7, 1996, Pages 1242-1256

  Volkow, Nora D ^a   Fowler, Joanna S ^b   Gatley, S John ^b   Logan, Jean ^b   Wang, Gene Jack ^b   Ding, Yu Shin ^b   Dewey, Stephen ^b  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b NONE

Author keywords

imaging; neurological illnesses; neurotransmitters; pharmacology; psychiatric illnesses

Indexed keywords

1 [2 [(4 FLUOROPHENYL)(PHENYL)METHOXY]ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 PHENYL 1H 3 BENZAZEPINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 5 (2,3 DIHYDROBENZOFURAN 7 YL) 2,3,4,5 TETRAHYDRO 3 METHYL 8 NITRO 1H 3 BENZAZEPIN 7 OL; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; 8 CHLORO 5 (2,3 DIHYDROBENZOFURAN 7 YL) 2,3,4,5 TETRAHYDRO 3 METHYL 1H 3 BENZAZEPIN 7 OL; CARBON 11; CATECHOL METHYLTRANSFERASE; CLORGYLINE; CLOZAPINE; COCAINE DERIVATIVE; ECOPIPAM; EPIDEPRIDE; FLUORINE 18; IODINE 123; LAZABEMIDE; LEVODOPA; LITHIUM; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; NEUROLEPTIC AGENT; NOMIFENSINE; RACLOPRIDE; RADIOPHARMACEUTICAL AGENT; SELEGILINE; TRITIUM; UNINDEXED DRUG; VANOXERINE;

BRAIN BLOOD FLOW; BRAIN METABOLISM; DEGENERATIVE DISEASE; DOPAMINE METABOLISM; DOPAMINERGIC TRANSMISSION; ENZYME ACTIVITY; GLUCOSE METABOLISM; HUMAN; LIGAND BINDING; MENTAL DISEASE; NEURORADIOLOGY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; SECOND MESSENGER; SUBSTANCE ABUSE;

BRAIN; CARRIER PROTEINS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; RECEPTORS, DOPAMINE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0029738423     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (254)

1. Goldman-Rakic P. Circuitry of the prefrontal cortex. In: Plum F, ed. Handbook of psychology. Bethesda, MD: American Physiological Society; 1987:373-417.
2. LeMoal M, Simon H. Mesocorticolimbic dopamine network: functional and regulatory roles. Physiol Rev 1991;71:155-234.
3. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science 1988;242:715-723.
4. Kopin IJ. The pharmacology of Parkinson's disease therapy: an update. Ann Rev Pharmacol Toxicol 1993;32:467-495.
5. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481-483.
6. McGeer PL, McGeer EG, Suzuki JS. Aging and extrapyramidal function. Arch Neurol 1977;34:33-35.
7. Weeks RA, Brooks DJ. Positron emission tomography and central neurotransmitter systems in movement disorders. Fundam Clin Pharmacol 1994;8:503-517.
8. Volkow ND, Fowler JS. Neuropsychiatric disorders: investigation of schizophrenia and substance abuse. Semin Nucl Med 1992;22:254-267.
9. Di Chiara G, Morelli M, Acquas E, Carboni E. Functions of dopamine in the extrapyramidal and limbic systems. Arzneim-Forsch Drug Res 1992;42:231-237.
10. Willner P, Muscat R, Papp M, Sampson D. In: Willner P, Scheel-Kruger J, eds. The mesolimbic dopamine system: from motivation to action. New York, NY: John Wiley and Sons; 1992:387-400.
11. Glowinski J, Tassin JP, Thierry AM. The mesocortical-prefrontal dopaminergic neurons. TINS 1984:418-451.
12. Selemon LD, Goldman Rackic PS. Longitudinal topography and interdigitations of corticostriatal projections in the rhesus monkey. J Neurosci 1984;5:776-794.
13. Stuss DT, Benson DF. The frontal lobes. New York, NY: Raven Press; 1986:12-38.
14. McGeer PL, Eccles JC, McGeer EG. Physiology and pharmacology of dopamine. Molecular neurobiology of the mammalian brain. New York, NY: Plenum Press; 1987:294-308.
15. Garris PA, Ciolkowski EL, Pastore P, Wightman RM. Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J Neurosci 1994; 14:6084-6093.
16. Jackson DM, Westlind-Danielsson A. Dopamine receptors: molecular biology, biochemistry and behavioral aspects. Pharmacol Ther 1994;64:291-369.
17. Fowler JS, Wolf AP. New directions in positron emission tomography. In: Bristol JA, ed. Annual reports in medicinal chemistry. 1989;24:277-286.
18. 11C. J Nucl Med 1970;11: 474-478.
19. Chumpradil S, Kung MP, Billings J, Kung HF. Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT. J Med Chem 1993;36:221-228.
20. Seeman P, Niznik H. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J 1990;4:2737-2744.
21. Sibley DR, Monsma FJ. Molecular biology of dopamine receptors. Trends Pharmacol Sci 1992;13:61-69.
22. 125I]epidepride. Brain Res 1993;609:237-243.
23. Starr MS. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse 1995;19:264-293.
24. Camps M, Cortes R, Gueye B, Probst A, Palacios JM. Dopamine receptors in human brain autoradiographic distribution of D2 sites. Neuroscience 1989;28:275-290.
25. Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in human brain. Neuropsychopharmacology 1994;11:245-256.
26. 125I]epidepride. Eur J Pharmacol 1992;227:443-445.
27. Seeman P, Guan H, Van Tol H. Dopamine D4 receptors elevated in schizophrenia. Nature 1993;365:441-445.
28. Strange PG. Dopamine D4 receptors: curiouser and curiouser. Trends Pharmacol Sci 1994;15:317-319.
29. Meador-Woodruff JH, Mansour A, et al. Distribution of D5-dopamine receptor mRNA in rat brain. Neurosc Lett 1992;145:209-212.
30. Wagner HN, Burns HD, Dannals RF, et al. Imaging DA receptors in the human brain by PET. Science 1983;221:1264-1266.
31. 18F]-N-methylspiroperidol and PET. J Nucl Med 1986;27:1878-1882.
32. 76Br-bromospiroperidol: a new tool for quantitative in vivo imaging of neuroleptic receptors. Life Sci 1984;35:1349-1356.
33. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analyses of D2-dopamine receptor binding in the living human brain by positron emission tomography. Science 1986;231:258-260.
34. Halldin C. Dopamine receptor radioligands. Med Chem Res 1994;5:127-149.
35. 3H raclopride: implications for positron emission tomography of the human brain. Synapse 1989;3:96-97.
36. Wang G-J, Volkow ND, Logan J, et al. Evaluation of age-related changes in serotonin 5-HT2 and dopamine D2 receptor availability in healthy human subjects. Life Sci 1995;56:249-253.
37. VanTol HM, Bunzow JR, Guan C, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-614.
38. Huntley GW, Morrison JH, Prikhozhan A, Sealton SC. Localization of multiple dopamine receptor subtype mRNAs in human and monkey motor cortex and striatum. Mol Brain Res 1992;15:181-188.
39. Filloux F, Dawson TM, Wamsley JK. Localization of nigrostriatal dopamine receptor subtypes and adenylate cyclase. Brain Res Bull 1988;20:447-459.
40. Joyce JN, Marshall JF. Quantitative autoradiography of dopamine D2 sites in rat caudate-putamen: localization to intrinsic neurons and not to neocortical afferents. Neurosci 1987;20:773-794.
41. Farde L, Nordstrom A-L, Karlsson P, Halldin C, Sedvall G. Positron emission tomography. Studies on dopamine receptors in schizophrenia. Clin Neuropharmacol 1995;18:S121-S129.
42. Wang G-J, Volkow ND, Fowler JS, et al. Comparison of two PET radioligands for imaging extrastriatal dopamine receptors in human brain. Synapse 1993;15:246-249.
43. Yousef K, Volkow ND, Schlyer D, et al. Inhibition of extrastriatal dopamine receptors by haloperidol. Synapse 1995;19:14-17.
44. 125I]epidepride. Brain Res 1993;609: 237-243.
45. Halldin C, Farde L, Hogberg T, et al. Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 1995;36:1275-1281.
46. Wong DF, Gjedde A, Wagner HN. Quantification of neuroreceptors in the living human brain. I. Irreversible binding of ligands. J Cereb Blood Flow Metab 1986;6:136-146.
47. 11C raclopride. Psychopharmacology 1987;92:278-284.
48. Halldin C, Farde L, Barnett A, Sedvall G. Synthesis of carbon-11-labeled SCH 39166, a new selective dopamine D1 receptor ligand, and preliminary PET investigations. Appl Radiat Isot 1991;42:451-455.
49. 11C]NNC 756 as new radioligands for the D1-dopamine receptor. Psychopharmacology 1993;113:149-156.
50. 11C]NNC 112, a selective PET radioligand for examination of extrastriatal dopamine D1 receptors. J Nucl Med 1994;35:122P.
51. 11C]SKF 75670 as a potential dopamine D1 receptor agonist imaging agent for PET. J Labeled Compd Radiopharm 1994;35:460-461.
52. Wong DF, Wagner HN Jr, Dannals RF, et al. Effects of age on dopamine and serotonin receptors measured by positron emission tomography in the living brain. Science 1986;226:1393-1396.
53. 76Br]bromospiperone binding sites demonstrated by positron emission tomography in progressive supranuclear palsy. J Cereb Blood Flow Metab 1986;6:131-136.
54. 11C raclopride. Arch Neurol 1993;50:474-480.
55. 11C raclopride. J Cereb Blood Flow Metab 1993;13:310-314.
56. Seeman P, Bzowe NH, Guan HG, et al. Human brain dopamine receptors in children and aging adults. Synapse 1987;1:399-404.
57. Suhara T, Fukuda H, Inoue O. et al. Age-related changes in human D1 dopamine receptors measured by positron emission tomography. Psychopharmacology 1991; 103:41-45.
58. Andreasen NC, Carson R, Diksic M, et al. Workshop on schizophrenia, PET and the dopamine D2 receptors in the human neostriatum. Schiz Bull 1988;14:471-484.
59. Farde L, Nordstrom A-L, Wiesel FA, et al. Positron emission tomography analysis of central D1 and D2 receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-544.
60. 18F-N-methylspiroperidol PET studies to measure changes in antipsychotic drug D2 receptor occupancy in schizophrenic patients. Biol Psychiatry 1988;23:653-663.
61. Farde L, Nordstrom A, Nyberg S, Halldin C, Sedvall G. D1, D2 and 5HT2 occupancy in clozapine treated patients. J Clin Psychiatry 1994;55(suppl B):67-69.
62. Wolkin A, Brodie JD, Rotrosen J, et al. Dopamine receptor occupancy and plasma haloperidol levels. Arch Gen Psychiatry 1989;46:482-483.
63. Cambon H, Baron JC, Boulenger JP. In vivo assay for neuroleptic receptor binding in the striatum positron tomography in humans. Br J Psychiatry 1987;151:824-830.
64. Carlsson A. Towards a new understanding of dopamine receptors. Clin Neuropharmacol 1995;18:S6-S13.
65. Wolkin A, Barouche F, Wolf AP, et al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989;46: 905-908.
66. Coppens W, Sloff CJ, Paans AMJ, et al. High central D2 dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients. Biol Psychiatry 1991;29:629-634.
67. Volkow ND, Fowler JS, Wolf AP, et al. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry 1990;147:719-724.
68. Volkow ND, Fowler JS, Wang G-J, et al. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 1993;14:169-177.
69. Hietala J, West C, Syvalahti E, et al. Striatal D2 dopamine receptor binding characteristics in vivo in patients with alcohol dependence. Psychopharmacology 1994;116:285-290.
70. Pearlson GD, Wong DF, Tune LE, et al. In vivo dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch Gen Psychiatry 1995;52:471-477.
71. Suhara T, Nakayama K, Inoue O, et al. D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology 1992; 106:14-18.
72. Caldecott-Hazzard S, Morgan DG, De Leon-Jones F, et al. Clinical and biochemical aspects of depressive disorders. II. Transmitter/receptor theories. Synapse 1991;9: 251-301.
73. Brown AS, Gershon S. Dopamine and depression. J Neural Transm [Gen Sect] 1993;91:75-109.
74. Aquilonius SM. What has PET told us about Parkinson's disease? Acta Neurol Scand 1991;136:37-39.
75. Rinne UK, Laihinen A, Rinne JO, et al. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord 1990;5:55-59.
76. Hassan MM, Thakar J. Dopamine receptors in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:173-182.
77. Rinne JO, Laihinen A, Lannberg P, Maramaki P, Rinne UK. A postmortem study on striatal dopamine receptors in Parkinson's disease. Brain Res 1991;556:117-122.
78. 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology 1992;41: 556-561.
79. Leenders K, Frackowiak R, Quinn N. Brain energy metabolism and dopaminergic functions in Huntington's disease measured in vivo using positron emission tomography. Mor Disord 1986;1:69-77.
80. 11C-N-methylspiperone. Acta Neurol Scand 1987;75:87-94.
81. Brandt J, Folstein S, Wong D, et al. D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates. J Neuropsychiatry Clin Neurosci 1990;2:20-27.
82. Sedvall G, Karlsson P, Lundin A, et al. Dopamine D1 receptor number - a sensitive PET marker for early brain degeneration in Huntington's disease. Eur Arch Psychiatry Clin Neurosci 1994;243:249-255.
83. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self administration of cocaine. Science 1987;237:1219-1223.
84. 11C]nomifensine uptake using positron emission tomography. J Cereb Blood Flow Metab 1990;10:307-317.
85. 11C nomifensine and positron emission tomography: the effect of age and Parkinson's disease. Acta Neurol Scand 1988;77: 92-101.
86. Fowler JS, Volkow ND, Wolf AP, et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse 1989;4:371-377.
87. 18F]GBR 13119 to the brain dopamine uptake system. Life Sci 1988;42:1347-1351.
88. 11C]fluoxetine (5-HT). J Lab Cmpd Radiopharm 1989;26:412-414.
89. 18F]GBR 12909, a dopamine uptake inhibitor. J Nucl Med 1990;31:720.
90. Innis RB, Seibyl JP, Scanley BE, et al. Single-photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA 1993;90:11965-11969.
91. Laihinen AO, Rinne JO, Nagren KA, et al. PET studies on brain monoamine transporters with carbon-11-β-CIT in Parkinson's disease. J Nucl Med 1995;36: 1263-1267.
92. Madras BK, Spealman RD, Fahey MA, et al. Cocaine receptors labeled by 2β-carbomethoxy-3β-(4-fluorophenyl)tropane. Mol Pharm 1989;36:518-524.
93. 11C]WIN 35, 428. Synapse 1993;15:130-142.
94. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Am J Neurol 1993;34:423-431.
95. 11C]d-threo-methylphenidate for the presynaptic dopaminergic neuron. Synapse 1994;18:152-160.
96. 11C]d-threo-methylphenidate: a new PET ligand for the dopamine transporter. II. Studies in the human brain. J Nucl Med 1995;36:2162-2168.
97. 11C-nomifensine and positron emission tomography. Acta Neurol Scand 1987;76:283-287.
98. 11C]cocaine binding at sub-pharmacological and pharmacological doses: a PET study. J Nucl Med 1995;36: 1289-1297.
99. 11C]tetrabenazine and positron emission tomography. J Neurochem 1993;60:2315-2318.
100. Kilbourn MR. Shades of grey: radiopharmaceutical chemistry in the 1990s and beyond. Nucl Med Biol 1992;19:603-606.
101. Volkow ND, Fowler JS, Wang G-J, et al. Decreased dopamine transporters with age in healthy human subjects. Ann Neurology 1994;36:237-239.
102. Van Dick CH, Seibyl JP, Malison RT, et al. Age-related decline in dopamine transporter binding in human striatum with [I-123]β-CIT SPECT. J Nucl Med 1995;36:1175-1181.
103. Zelnik N, Angel I, Paul SM, Kleinman JE. Decreased density of human striatal dopamine uptake sites with age. Eur J Pharmacol 1986;126:175-176.
104. De Keyser J, Ebinger G, Vauquelin G. Age-related charges in the human nigrostriatal dopaminergic system. Ann Neurol 1990;27:157-161.
105. 123I]βCIT. Soc Neurosci Abstr 1994;20:1625.
106. Volkow ND, Wang G-J, Fowler JS, et al. Cocaine binding is decreased in the brain of detoxified cocaine abusers. J Neuropsychopharmacol 1996;14:159-168.
107. Tiihonen J, Kuikka J, Bergstrom K, et al. Altered striatal dopamine reuptake site densities in habitually violent and nonviolent alcoholics. Nature Medicine 1995;1: 654-657.
108. Zhu M-Y, Juorio AV. Aromatic L-amino acid decarboxylase: biological characterization and functional role. Gen Pharmacol 1995;26:681-696.
109. 14C]methyl-para-tyrosine in the rat. Synapse 1994;17:125-128.
110. 18F]fluoro-α-fluoromethyl-p-tyrosine, a potential PET tracer for tyrosine hydroxylase activity. Nucl Med Biol 1994;21:663-667.
111. Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 1983;305:137-138.
112. 18F]Fluoro-dopa, an analog of dopa, and its use in direct external measurements of storage, degradation and turnover of intracerebral dopamine. Proc Nat Acad Sci USA 1978;75:464-467.
113. 18F]Fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods. J Cereb Blood Flow Metab 1993;13:57-69.
114. Dhawan V, Ishikawa T, Chaley T, et al. Combined FDOPA and 3OMFD PET studies in Parkinson's disease: modeling issues. J Nucl Med 1996;in press.
115. 18F]fluoro-L-dopa in rats, monkeys and humans. Life Sci 1990;47:149-157.
116. Gjedde A, Reith J, Dyve S, et al. Dopa decarboxylase activity in the living human brain. Proc Nat Acad Sci USA 1991;88:2721-2725.
117. 11C)-L-dopa following COMT inhibition. A study in vivo using positron emission tomography. J Neurol Transm 1992;87:15-22.
118. 3H]L-dopa in rats. Biochem Pharm 1990;39:1853-1860.
119. 11C]DOPA in humans studied by positron emission tomography. J Neurol Transm 1991;86:25-41.
120. 11C]L-DOPA in healthy volunteers and patients with unipolar depression. Depression 1993;1:71-81.
121. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993;34:324-330.
122. 18F-DOPA uptake: absence of an aging effect. J Cereb Blood Flow Metab 1993;13:881-888.
123. Martin WRW, Palmer MR, Patlak CS, Calne DB. Nigro-striatal function in man studied with positron emission tomography. Ann Neurol 1989;26:535-542.
124. Sawle GV, Colebatch JG, Shah A, et al. Striatal function in normal aging: implications for Parkinson's disease. Ann Neurol 1990;28:799-804.
125. Kish SJ, Zhong XH, Homykiewicz O, et al. Striatal 3,4-dihydroxyphenylalanine decarboxylase in aging: disparity between postmortem and positron emission tomography studies. Ann Neurol 1995;38:260-264.
126. Holthoff VA, Kessler J, Pietrzyk U, et al. Motor and cognitive deficits in Parkinson's disease are related to striatal dopamine uptake [Abstract]. J Cereb Blood Flow Metab 1993;13:S253.
127. DeJesus OT, Mukhergee J. Radiobrominated m-tyrosine analogs as potential CNS L-dopa PET tracers. Biochem Biophys Res Commun 1988;150:1027-1031.
128. 18F]Fluoro-L-m-tyrosine: An L-3,4-dihydroxyphenylalanine analog for probing presynaptic dopaminergic function with positron emission tomography. J Neurochem 1989;53:311-314.
129. 18F]6-fluoro-L-m-tyrosine in the human brain. Mov Disord 1995;10:298-304.
130. 18F]fluoro-β-fluoromethylene-m-tyrosine. Brain Res 1992;597:151-154.
131. Berry MD, Juorio AV, Paterson IA. The functional role of monoamine oxidases A and B in the mammalian central nervous system. Prog Neurobiol 1994;42:375-391.
132. Breakefield XO, Chen Z-Y, Tivol E, Shalish C. Molecular genetics and inheritance of human monoamine oxidases A and B. Neurol Dis Ther 1994;21:95-112.
133. Youdim MBH, Riederer P. Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition. J Neural Transm 1993;91:181-195.
134. O'Carroll M, Fowler CJ, Phillips JP, et al. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Arch Pharmacol 1983;322:198-202.
135. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968;17:1285-1297.
136. Knoll J, Magyar K. Some puzzling effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 1972;5:393-408.
137. Oreland L, Arai Y, Stenstrom A, Fowler CJ. Monoamine oxidase activity and localization in the brain and the activity in relation to psychiatric disorders. Mod Prob Pharmacopsychiatry 1983; 19:246-254.
138. Riederer P, Konradi C, Schay V, et al. Localization of MAO A and MAO B in human brain: a step in understanding the therapeutic action of L-deprenyl. In: Yahr MD. Bergman KJ, eds. Advances in Neurology. New York, NY: Raven Press, 1986:111-118.
139. Strolin, Benedetti M, Dosten P. Monoamine oxidase: from physiology and pathophysiology to the design and clinical application of reversible inhibitors. Adv Drug Research 1992;23:67-125.
140. Birkmayer W, Knoll J, Youdim MBH, et al. Increased life expectancy resulting from addition of L-deprenyl to L-DOPA treatment in Parkinson's disease: a longterm study. J Neurol Transm 1985;64:113-127.
141. Tetrud JW, Langston JW. The effect of deprenyl (selegeline) on the natural history of Parkinson's disease. Science 1989;245:519-522.
142. Olanow CW, Calne D. Does selegeline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms? Neurology 1991;41 (suppl 4):13-26.
143. 11C-suicide inactivators and positron emission tomography. Science 1987;235:481-485.
144. 11C]N,N-dimethylphenethylamine in mice and humans: potential for measurement of brain MAO B activity. J Nucl Med 1987;28:1006-1011.
145. 11C]L-deprenyl-D2 for MAO B mapping. J Nucl Med 1995;36:1255-1262.
146. Fowler JS, Volkow ND, Logan J, et al. Slow recovery of human brain MAO B after L-Deprenyl (selegeline) withdrawal. Synapse 1994;18:86-93.
147. Bench CJ, Price GW, Lammertsma AA, et al. Measurement of human cerebral monoamine oxidase B (MAO B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19 6327. Eur J Clin Pharmacol 1991;10:169-173.
148. Fowler JS, Volkow ND, Logan J, et al. MAO B inhibition therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by RO 196327. Neurology 1993;42:1984-1992.
149. Guldberg HC, Marsden CA. Catechol-O-methyltransferase: pharmacological aspects and physiological role. Pharmacol Rev 1975;27:135-206.
150. Mannisto TP, Kaakkola S. New selective COMT inhibitors: useful adjuncts for Parkinson's disease? TIPS 1989;10:34-36.
151. Wood PL, Altar CA. Dopamine release in vivo from nigrostriatal mesolimbic and mesocortical neurons: utility of 3-methoxytyramine measurements. Pharmacol Rev 1988;40:163-187.
152. Axelrod J. The O-methylation of epinephrine and other catechols in vitro and in vivo. Science 1957;126:1657-1660.
153. Mannisto PT, Kaakkola S, Nissinen E, et al. Potent, selective and orally active inhibitors of catechol-O-methyltransferase. Life Sci 1988;32:1465-1471.
154. 18K] Ro41-0960. Life Sci 1995;58:195-208.
155. Friedman AM, DeJesus OJ, Revenaugh J, et al. Measurements in vivo of parameters of the dopamine system. Ann Neurol 1984;15:S66-S76.
156. 3H raclopride in the mouse in vivo. Arch Pharmacol 1989;340:6-12.
157. 11C-raclopride and positron emission tomography. J Neurosci 1992;12:3773-3780.
158. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 1993;13:350-356.
159. Hume SP, Myers R, Bloomfield PM, et al. Quantitation of carbon-11-labeled raclopride in rat striatum using positron emission tomography. Synapse 1992;12:47-54.
160. 11C]raclopride in the human brain. Synapse 1994;16:255-262.
161. 18F] N-methylspiroperidol binding in baboon brain using positron emission tomography (PET). Synapse 1991;7:324-327.
162. 18F]N-methylspiroperidol binding in the basal ganglia: comparison of simulations and experimental results from PET studies in baboons. Synapse 1991;9:195-207.
163. 11C]raclopride binding in healthy young adults and schizophrenic patients, reliability and age effects. Human Psychopharmacol 1992;7:157-165.
164. 11C raclopride binding in the human brain. J Nucl Med 1993;34:609-613.
165. Lamelle M, Abi-Dargham A, van Dick C, et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 1995;36:1182-1190.
166. Wang G-J, Volkow ND, Fowler JS, et al. Methylphenidate decreases regional cerebral blood flow in normal human subjects. Life Sci 1994;54:1433-1446.
167. 11C] raclopride binding in the brain: model simulations and kinetic analysis of PET data. J Cereb Blood Flow Metab 1994,14:995-1010.
168. 3H]N-methylspiperone. Neuropharmacol 1991;30:1101-1106.
169. Deterding LJ, Dix K, Burka LT, Tomer KB. On-line coupling of in vivo microdialysis with tandem mass spectrometry. Anal Chem 1992;64:2636-2641.
170. Gifford AN, Gatley SJ, Ashby CR. Endogeneously released dopamine inhibits the binding of dopaminergic PET and SPECT ligands in superfused rat striatal slices. Synapse 1990;22:232-238.
171. Riederer P, Lange KW, Kornhuber J, et al. Glutamatergic-dopaminergic balance in the brain: its implications in motor disorders and schizophrenia. Arzneim-Forsch 1992;42:265-268.
172. Meltzer H. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacol 1989;99:S18-S27.
173. Schaefer GJ. Opiate antagonists and rewarding brain stimulation. Neurosci Behav Rev 1988;12:1-17.
174. Girault JA, Halpain S, Greengard P. Excitatory amino acid antagonists and Parkinson's disease. Trends Neurosci 1990;13:325-326.
175. Stockmeier CA, DiCarlo JJ, Zhang Y, et al. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin-2 and dopamine-2 receptors. J Pharmacol Exp Ther 1993;266:1374-1384.
176. Dewey SL, Brodie JD, Fowler JS, et al. Positron emission tomography studies of dopaminergic/cholinergic interactions in the baboon brain. Synapse 1990;6:321-327.
177. Dewey SL, Smith GS, Logan J, et al. Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. Proc Natl Acad Sci USA 1993;90:11816-11820.
178. Dewey SL, Smith GS, Logan J, et al. Serotonergic modulation of striatal dopamine measured with positron emission tomography and in vivo microdialysis. J Neurosci 1995;15:821-829.
179. 11C-raclopride [Abstract]. Soc Neurosci Abstr 1993;19:128.9.
180. Ingvar M, Stone-Elander S, Rogers G, et al. Striatal D2/acetylcholine interactions: PET studies of the vesamicol receptor. NeuroReport 1993;4:1311-1314.
181. Reith J, Benkelfat C, Sherwin A, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 1994;91:11651-11654.
182. Grace AA. Phasic versus tonic dopamine release and the modulation of the dopamine system responsivity. Neurosci 1991;41:1-24.
183. 18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 1979;44:127-137.
184. Mata M, Fink DJ, Gainer H. Activity-dependent energy metabolism in rat posterior pituitary primarily reflects sodium pump activity. J Neurochem 1980;34:213-215.
185. 14C]deoxyglucose method for measurement of local cerebral glucose utilization. J Neurochem 1977;28:897-916.
186. 14C]deoxyglucose method. Modern methods in pharmacology, volume 6, testing and evaluation of drugs of abuse. New York, NY: Wiley-Liss; 1990:147-164.
187. Wolkin A, Angrist B, Wolf A, et al. Effects of amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography. Psychopharmacol 1987;92:241-246.
188. London ED, Cascella NG, Wong DF, et al. Cocaine-induced reduction of glucose utilization in human brain. A study using positron emission tomography and [fluorine-18]-fluorodeoxyglucose. Arch General Psychiatry 1990;47:567-574.
189. Volkow ND, Brodie JD, Wolf AP, et al. Brain metabolism in schizophrenics before and after acute neuroleptic administration. J Neurol Neurosurg Psychiatry 1986;49: 1199-1202.
190. Bartlett EJ, Brodie JD, Simkowitz P, et al. Effects of haloperidol challenge on regional cerebral glucose utilization in normal human subjects. Am J Psychiatry 1994;151:681-686.
191. Wolkin A, Jaeger J, Brodie JD, et al. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography. Am J Psychiatry 1985;142:564-571.
192. DeLisi LE, Holcomb HH, Cohen RM, et al. Positron emission tomography in
193. Buchsbaum MS, Wu JC, DeLisi LE, et al. Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects. Biol Psychiatry 1987;22:479-494.
194. Szechtman H, Nahmias C, Garnett ES, et al. Effect of neuroleptics on altered cerebral glucose metabolism in schizophrenia. Arch Gen Psychiatry 1988;45:523-532.
195. Wik G, Wiesel F-A, Sjorgen I, et al. Effects of sulpiride and chlorpromazine on regional cerebral glucose metabolism in schizophrenic patients as determined by positron emission tomography. Psychopharmacol 1989;97:309-318.
196. Buchsbaum MS, Potkin SG, Siegel BV Jr, et al. Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch Gen Psychiatry 1992;49:966-974.
197. Bartlett EJ, Wolkin A, Brodie JD, et al. Importance of pharmacologic control in PET studies: effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophrenia. Psychiatry: Res 1991;40:115-124.
198. Holcomb HH, Cascella NG, Thaker GK, et al. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am J Psychiatry 1996;153:41-49.
199. 18F-fluorodeoxyglucose and positron emission tomography. Neurology 1995;45:1995-2004.
200. 18F-fluorodopa positron emission tomography studies. Mov Disord 1990;5:203-213.
201. Swart JAA, Korf J. In vivo dopamine receptor assessment for clinical studies using positron emission tomography. Biochem Pharmacol 1987;36:2241-2250.
202. Mintun MA, Raichle ME, Kilbourn MR, et al. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984;15:217-227.
203. Wong DF, Gjedde A, Wagner HN, et al. Quantification of neuroreceptors in the living human brain. II. Inhibition studies of receptor density and affinity. J Cereb Blood Flow Metab 1986;6:147-153.
204. 11C]raclopride binding to D2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 1989;9:696-708.
205. Perlmutter JS, Larson KB, Raichle ME, et al. Strategies for in vivo measurement of receptor binding using positron emission tomography. J Cereb Blood Flow Metab 1986;6:154-169.
206. Logan J, Wolf AP, Shiue C-Y, Fowler JS. Kinetic modeling of a receptor-ligand binding applied to positron emission tomographic studies with neuroleptic tracers. J Neurochem 1987;48:73-83.
207. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983;3:1-7.
208. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalization. J Cereb Blood Flow Metab 1985;5: 584-590.
209. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990;10:740-747.
210. 11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab 1991;11:735-744.
211. Carson RE. Parameter estimation in positron emission tomography. In: Phelps M, Mazziotta J, Schelbert H, eds. Positron emission tomography and autoradiography: principles and applications for the brain and heart. New York, NY: Raven Press; 1986:347-390.
212. Huang S-C, Barrio JR, Phelps ME. Neuroreceptor assay with positron emission tomography: equilibrium versus dynamic approaches. J Cereb Blood Flow Metab 1986;6:515-521.
213. Zeeberg BR, Gibson RE, Reba RC. Accuracy of in vivo neuroreceptor quantification by PET and review of steady-state, transient, double injection and equilibrium models. IEEE Trans Med Imaging 1988;7:203-215.
214. Delforge J, Syrota A, Mazoyer BM. Experimental design optimization: theory and application to estimation of receptor model parameters using dynamic positron emission tomography. Phys Med Biol 1989;34(4):419-435.
215. Logan J, Schlyer DJ, Wolf AP, et al. Antipsychotics D-2 receptor occupancy and plasma concentration. Biol Psychiatry (Letter) 1990;28:1068-1070.
216. 11C]flumazenil. J Cereb Blood Flow Metab 1991;11:745-752.
217. 18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 1993;13:24-42.
218. Wong DF, Wagner HN Jr, Tune LE, et al. Positron emission tomography reveals elevated D2-dopamine receptors in drug-naive schizophrenics. Science 1986;234: 1558-1563.
219. Farde L, Wiesel F-A, Stone-Elander S, et al. D2-dopamine receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatry 1990;47:213-219.
220. Votaw JR, Kessler RM, De Paulis T. Failure of the three-compartment model to describe the pharmacokinetics in brain of a high affinity substituted benzamide. Synapse 1993;15:177-190.
221. Samana P, Cottechia S, Costa T, Lefkowitz RJ. A mutation-induced activated state of the β2-adrenergic receptor. J Biol Chem 1993;268:4625-4636.
222. Costa T, Ogino Y, Munson PJ, et al. Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol Pharmacol 1992;41: 549-560.
223. Black JW, Shankley NP. Inverse agonists exposed. Nature 1995;374:214-215.
224. Bond RA, Leff P, Johnson TD, et al. Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the β2-adrenoceptor. Nature 1995;374:272-276.
225. Leff P. The two-state model of receptor activation. Trends Pharmacol Sci 1994;15: 408-409.
226. Milligan G, Bond RA, Lee M. Inverse agonists: pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol Sci 1995;16:10-13.
227. Tiberi M, Caron MC. Constitutive activity of dopamine D1 receptor subtypes. Clin Neuropharmacol 1995;18:S43-S48.
228. Robinson PR, Cohen GB, Zhukovsky EA, Oprian DD. Constitutively active mutants of rhodopsin. Neuron 1992;9:719-725.
229. Parma J, Duprez L, Van Sande J, et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993;365:649-651.
230. Yang Z-Y, Mukherjee J. Development of agonists as radiotracers for the assessment of the functional state of the dopamine D2 receptors [Abstract]. J Nucl Med 1995;36(suppl):152P.
231. Manji HK, Chen G, Simon H, et al. Guanine nucleotide-binding proteins in bipolar affective disorder. Arch Gen Psychiatry 1995;52:135-144.
232. Nestler EJ. Molecular neurobiology of drug addiction. Neuropsychopharmacol 1994;11:77-88.
233. Manji HK, Potter WZ, Lenox RH. Signal transduction pathways. Molecular targets for lithium's actions. Arch Gen Psychiatry 1995;52:531-543.
234. 18F]Labeled 1,2-diacylglycerols; a new tracer for the imaging of second messenger system [Abstract]. J Labeled Compds Radiopharm 1994;35:517-519.
235. Dewanjee MK, Ghafouripour AK, Boothe T, et al. Gallium-67 labeling of antisense deoxyoligonucleotide (GAASDON) probes and uptake in leukemic cells (P388) [Abstract]. J Labeled Compd Radiopharm 1994;35:356-357.
236. Schrell UM, Nomikos P, Fahlbusch R. Presence of dopamine D1 receptors and absence of dopamine D2 receptors in human cerebral meningioma tissue. J Neurosurg 1992;77:288-294.
237. 11C-N-methylspiperone. J Comp Assist Tomog 1986;10:175-180.
238. Luabeya MK, Maloteaux JM, Laduron PM. Regional and cortical laminar distributions of serotonin S2, benzodiazepine, muscarinic and dopamine D2 receptors in human brain. J Neurochem 1984;43:1068-1071.
239. McElvain JS, Schenk JO. A multisubstrate mechanism of striatal dopamine uptake and its inhibition by cocaine. Biochem Pharmacol 1992;43:2189-2199.
240. Mackay AVP, Davies P, Dewar CM, Yates CM. Regional distribution of enzymes associated with neurotransmission by monoamines, acetylcholine and GABA in the human brain. J Neurochem 1978;30:827-839.
241. O'Carroll AM, Andersen MC, Tobbia I, et al. Determination of the absolute concentrations of monoamine oxidase A and B in human tissues. Biochem Pharmacol 1989;38:901-905.
242. Huh MM, Friedhoff AJ. Multiple molecular forms of catechol-O-methyltransferase. J Biol Chem 1979;254:299-308.
243. Kastner A, Anglade P, Bounaix C, et al. Immunohistochemical study of catechol-O-methyltransferase in the human mesostriatal system. Neurosci 1994;62:449-457.
244. Andersen PH, Gronvald FC, Hohlweg R, et al. NNC-112, NNC-687 and NNC-756: new, selective and highly potent dopamine D1-receptor antagonists. Eur J Pharmacol 1992;219:45-52.
245. 3H]SCH 23390 in vivo. Neuropharmacol 1992;31:115-121.
246. Farde L, Ehrin E, Eriksson L, et al. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acud Sci USA 1985;82:3863-3867.
247. 3H]raclopride in reserpine-treated mouse brain. J Neural Transm 1991;85:1-10.
248. 123I]IBZM: a potential CNS D2-dopamine receptor imaging agent. J Nucl Med 1989;30:88-92.
249. 123I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors. Life Sci 1991;49:617-628.
250. Pellevoisin C, Chalon S, Zouakia A, et al. Comparison of two radioiodinated ligands of dopamine D2 receptors in animal models: iodobenzamide and iodoethylspiperone. Life Sci 1993;52:1851-1860.
251. 123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982-994.
252. 11C]methylphenidate to the dopamine transporter in vivo: insensitivity to synaptic dopamine. Eur J Pharmacol 1995;281:141-149.
253. Volkow ND, Fowler JS, Wolf AP, et al. Distribution and kinetics of carbon-11-cocaine in the human body measured with PET. J Nucl Med 1992;33:521-525.
254. 3H-WIN 35,428. Synapse 1989;4:390-392.